Active substanceZinc bisvinylimidazole diacetateZinc bisvinylimidazole diacetate
Dosage form: & nbspcapsules
Composition:

Composition per one capsule

Active substance: zinc bisvinilimidazole diacetate (Acisol®) - 120.00 mg;

Excipients: lactose monohydrate - 215.75 mg, talc - 8.91 mg, silicon dioxide colloid - 3.59 mg, calcium stearate - 1.75 mg; hard gelatin capsule number 1 (gelatin -73.27665 mg, titanium dioxide-1.29999 mg, quinoline yellow dye-0,34488 mg, azorubin dye-0,00048 mg, blue patented dye-0,04926 mg, black diamond dye - 0,02874 mg).

Description:

Hard gelatin capsules No. 1, with an opaque white body, an opaque lid of green color. On the body and cap of the capsule is indicated "ATSIZOL®". The contents of the capsules are white or white powder with a slightly yellowish tint of color with a specific odor. The powder is hygroscopic, it is allowed to clump.

Pharmacotherapeutic group:Antidote
ATX: & nbsp

V.03.A.B   Antidotes

Pharmacodynamics:

It is known that under the influence of elevated concentrations of carbon monoxide (II), the so-called Holden effect is manifested when, as a result of cooperative interaction of the heme 4 hemoglobin, the hemoglobin molecule is deprived of the ability to give oxygen, if the remaining 3 heme bound carbon monoxide (II). Acizol®, being a complex organozinc compound, due to a decrease in the cooperativity of the hemes and the relative affinity of hemoglobin to carbon monoxide (II), inhibits the formation of carboxyhemoglobin, which improves the oxygen-binding and gas transport properties of blood upon carbon monoxide poisoning, accelerates the elimination of carbon monoxide II) from the body. Increase in the affinity of hemoglobin for oxygen (O2) and the shift of the dissociation curve of oxyhemoglobin to the left allow hemoglobin to be completely saturated with oxygen at much lower O2 partial pressures, which increases the body's resistance to a lack of oxygen in the environment. Difficulty in recoil2 tissue leads to a relative deterioration in the supply of O2 only organs and tissues with a high threshold of its assimilation, while vital organs with a low threshold of assimilation of O2, for example, the brain, are in a better situation than in the absence of a left shift.

Acizol®, promoting the acceleration of elimination of carbon monoxide from the body,reduces the severity of intoxication during carbon monoxide (II) poisoning in terms of the severity of metabolic acidosis. It replenishes zinc deficiency in the body.

Pharmacokinetics:

Zinc bisvinilimidazole diacetate is quickly absorbed from the gastrointestinal tract. The maximum concentration in the blood plasma is reached after 1-1,5 hours. It is mainly metabolized by the liver. Metabolism products are excreted through the gastrointestinal tract. The half-life is 1-1.5 hours, after 8-10 hours, trace amounts of the drug are recorded.

Indications:

Poisoning with carbon monoxide (II) of varying severity (prevention and treatment).

Contraindications:

Hypersensitivity to the main and / or auxiliary components of the drug; breast-feeding; children under 18 years of age (due to insufficient data).

Carefully:Deficiency of copper.
Pregnancy and lactation:

In experimental studies on animals, embryotoxic and teratogenic properties, as well as adverse effect on the reproductive function of zinc bisvinilimidazole diacetate, were not revealed. Adequate and strictly controlled studies involving pregnant women were not conducted.The use of Aczizol in pregnant women as an antidote for carbon monoxide (II) poisoning is justified.

There are no data on the penetration of zinc bisvinilimidazole diacetate into breast milk. During the period of using the drug Acizol®, breastfeeding should be stopped.

Dosing and Administration:

Inside.

With the preventive purpose - 1 capsule (120 mg) for 30-40 minutes before entering the smoke (gas) zone, with a high risk of CO inhalation, during the work to eliminate the consequences of accidents and catastrophes, accompanied by fires, or when extinguishing the fires themselves and rescue of the victims. The protective effect is maintained for 2-2.5 hours. Repeated reception of the drug Acizol® is allowed after 1.5-2 hours. Due to the specificity of the action, safety and the absence of negative effects on physical and mental performance, prolonged exposure or poisoning with carbon monoxide (II), the use of the drug Acizol® is allowed - on the first day of 1 capsule (120 mg) 4 times, 1 capsule 2 times a day for 7 days. The maximum daily dose for an adult is 480 mg (4 capsules).When poisoning with carbon monoxide (II), the use of the drug Acizol® is recommended to start at the earliest possible time along with other medications.

Side effects:

When you take an empty stomach, you may experience a feeling of nausea.

Overdose:

Symptoms: metallic taste in the mouth, headache, nausea.

These phenomena occur after the drug is discontinued.

Interaction:

It is not recommended to be used together with sodium dimercaptopropanesulfonate.

When combined with other drugs, no negative effects were observed.

Special instructions:

The drug Acizol® contains lactose, therefore it is not recommended for patients who have rare hereditary lactose intolerance problems, lactase deficiency or glucose-galactose malabsorption syndrome.

Effect on the ability to drive transp. cf. and fur:The drug Acizol® does not adversely affect the ability to manage transport and mechanisms.
Form release / dosage:

Capsules of 120 mg.

Packaging:

1, 3 or 10 capsules in a contour cell box made of a polyvinyl chloride or polyvinyl chloride / polyvinylidene chloride film and aluminum foil.

For 1 contour cell package according to D or 3 capsules or 1, 2 or 3 contour packs of 10 1 capsules together, with instructions for use put in a cardboard pack.

For hospitals or the formation of first-aid kits of special purpose:

For 50, 100 contour packs of 1.3 or 10 capsules, together with instructions for use, are placed in a carton box. The number of instructions should correspond to the number of contiguous cell packs.

Storage conditions:

In a dry, protected from light place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription
Registration number:LS-001061
Date of registration:23.06.2011
Expiration Date:Unlimited
The owner of the registration certificate:Nizhny Novgorod Chemical and Pharmaceutical Plant, OJSCNizhny Novgorod Chemical and Pharmaceutical Plant, OJSC
Manufacturer: & nbsp
Information update date: & nbsp01.10.2017
Illustrated instructions
    Instructions
    Up